T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases

Katz, Steven C.; Donkor, Charan; Glasgow, Kristen; Pillarisetty, Venu G.; Gönen, Mithat; Espat, N. Joseph; Klimstra, David S.; D’Angelica, Michael I.; Allen, Peter J.; Jarnagin, William R.; DeMatteo, Ronald P.; Brennan, Murray F.; Tang, Laura H.

doi:10.1111/j.1477-2574.2010.00231.x

Cited by 82 publications

(87 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…+ and CD8 + TILs could not (17). Yet, the primary sites of the metastasis were not only the pancreas but also the small bowel and other in the present study.…”

Section: Discussioncontrasting

confidence: 58%

Impact of the tumor microenvironment in predicting postoperative hepatic recurrence of pancreatic neuroendocrine tumors

Sato¹,

Tsuchikawa²,

Nakamura³

et al. 2014

Oncology Reports

View full text Add to dashboard Cite

The disease frequency of pancreatic neuroendocrine tumors (PNETs) has been growing, and postoperative hepatic recurrence (PHR) is one of the factors affecting patient prognosis. The present study aimed to investigate biomarkers of PNETs in the primary disease site to predict PHR using immunohistochemical analysis for tumor-infiltrating lymphocytes (TILs: CD3, CD8 and CD45RO), human leukocyte antigen (HLA) class I, alpha-thalassemia/mental retardation X-linked (ATRX), death domain-associated protein (DAXX), mammalian target of rapamycin (mTOR) and phospho-mTOR (p-mTOR). Correlations were analyzed between TILs and the biomarkers, clinicopathological features and prognosis. Sixteen patients with PNETs who underwent radical surgery at our hospital were reviewed. We analyzed the correlation between PHR and immunohistochemical characteristics, and also between disease-free survival (DFS) or overall survival (OS) and the immunohistochemical characteristics. We found that PHR was associated with the expression patterns of DAXX and p-mTOR. No association was found between PHR and patient background, TILs or other biomarkers. DFS was found to be associated with ATRX, DAXX and p-mTOR. OS was associated only with p-mTOR. In conclusion, ATRX, DAXX and p-mTOR are useful molecular biomarkers for predicting PHR in patients who undergo radical surgery for PNETs. Use of these biomarkers will enable earlier decisions on which patients may benefit from adjuvant therapy

show abstract

“…+ and CD8 + TILs could not (17). Yet, the primary sites of the metastasis were not only the pancreas but also the small bowel and other in the present study.…”

Section: Discussioncontrasting

confidence: 58%

Impact of the tumor microenvironment in predicting postoperative hepatic recurrence of pancreatic neuroendocrine tumors

Sato¹,

Tsuchikawa²,

Nakamura³

et al. 2014

Oncology Reports

View full text Add to dashboard Cite

show abstract

“…They found a statistically significant difference in survival of intermediate grade (Ki 67 2-20%) PNET based on TIL density. Patients with dense T cell infiltration in tumor tissue had a median recurrence-free survival of 128 months as compared to 62 months in the subset with low TILs (p = 0.05) [19].…”

Section: Modern Immuno-oncology and Netsmentioning

confidence: 95%

Untitled

2018

Oncotarget

View full text Add to dashboard Cite

show abstract

“…That an immune response opposes to NETs is also substantiated by the frequent finding of lymphocyte infiltration of NETs, as assessed by immunohistochemistry for CD3 (a general T lymphocyte marker), CD4, and CD8 [61,62,63]. In the biggest case series analyzed so far, CD3+ T cells were found to infiltrate 68% of 87 well-differentiated pancreatic NETs.…”

Section: Immune Response To Nets: the Other Side Of The Coinmentioning

confidence: 97%

Diffuse Endocrine System, Neuroendocrine Tumors and Immunity: What’s New?

Ameri

Ferone²

2012

Neuroendocrinology

View full text Add to dashboard Cite

During the last two decades, research into the modulation of immunity by the neuroendocrine system has flourished, unravelling significant effects of several neuropeptides, including somatostatin (SRIH), and especially cortistatin (CST), on immune cells. Scientists have learnt that the diffuse neuroendocrine system can regulate the immune system at all its levels: innate immunity, adaptive immunity, and maintenance of immune tolerance. Compelling studies with animal models have demonstrated that some neuropeptides may be effective in treating inflammatory disorders, such as sepsis, and T helper 1-driven autoimmune diseases, like Crohn’s disease and rheumatoid arthritis. Here, the latest findings concerning the neuroendocrine control of the immune system are discussed, with emphasis on SRIH and CST. The second part of the review deals with the immune response to neuroendocrine tumors (NETs). The anti-NET immune response has been described in the last years and it is still being characterized, similarly to what is happening for several other types of cancer. In parallel with investigations addressing the mechanisms by which the immune system contrasts NET growth and spreading, ground-breaking clinical trials of dendritic cell vaccination as immunotherapy for metastatic NETs have shown in principle that the immune reaction to NETs can be exploited for treatment.

show abstract

T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases

Abstract: A robust T cell infiltrate is associated with improved RFS following resection of intermediate-grade NETs, whereas the presence of more Treg correlated with shorter OS after treatment of NETLMs. Further study of the immune response to intermediate-grade NETs and NETLMs is warranted.

Cited by 82 publications

References 27 publications

Impact of the tumor microenvironment in predicting postoperative hepatic recurrence of pancreatic neuroendocrine tumors

Impact of the tumor microenvironment in predicting postoperative hepatic recurrence of pancreatic neuroendocrine tumors

Untitled

Diffuse Endocrine System, Neuroendocrine Tumors and Immunity: What’s New?

Contact Info

Product

Resources

About